https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Systematic Review on the Influence of Tissue Oxygenation on Gut Microbiota and Anastomotic Healing https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42656 Wed 31 Aug 2022 13:02:16 AEST ]]> Biomarkers and anastomotic leakage in colorectal surgery: C-reactive protein trajectory is the gold standard https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36033 Wed 29 Jan 2020 11:59:09 AEDT ]]> A Pilot Study: Intraoperative 16S rRNA Sequencing Versus Culture in Predicting Colorectal Incisional Surgical Site Infection https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52909 Wed 22 May 2024 15:08:38 AEST ]]> Impact of avoiding post-operative urinary catheters on outcomes following colorectal resection in an ERAS programme: no IDUC and ERAS programmes https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33333 Wed 17 Oct 2018 13:27:31 AEDT ]]> C1q and mobility score in predicting sarcopenia in an Australian cohort of cancer surgery patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52162 Wed 04 Oct 2023 10:50:47 AEDT ]]> A systematic scoping review on natural killer cell function in colorectal cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46186 Tue 15 Nov 2022 08:43:55 AEDT ]]> Influence of the bile acid/microbiota axis in ileal surgery: a systematic review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55301 Tue 14 May 2024 17:51:09 AEST ]]> Venous thromboembolic prophylaxis: current practice of surgeons in Australia and New Zealand for major abdominal surgery https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53495 90% use all three forms of VTE prophylaxis at some stage of treatment. Most surgeons do not vary practice between laparoscopic and open colectomy/major abdominal surgery and only 33% prescribe post-discharge chemical prophylaxis. 42% of surgeons surveyed had equipoise for a clinical trial on the use of IPCDs and the vast majority (> 95%) feel that IPCDs should provide at least a 2% improvement in VTE event rate in order to justify their routine use. Conclusion: Most surgeons in Australia and New Zealand do not use risk assessment tools and use all three forms of prophylaxis regardless. Therfore there is a gap between practice and VTE prophylaxis for the use of mechanical prophylaxis options. Further research is required to determine whether dual modality mechanical prophylaxis is incrementally efficacious. Trial Registration- Not Applicable.]]> Thu 30 Nov 2023 15:43:30 AEDT ]]> Does postoperative inflammation or sepsis generate neutrophil extracellular traps that influence colorectal cancer progression? A systematic review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45013 Thu 27 Oct 2022 17:46:24 AEDT ]]> A meta-analysis on the effect of sham feeding following colectomy: should gum chewing be included in enhanced recovery after surgery protocols? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18423 Thu 25 Jun 2015 12:24:19 AEST ]]> Mobility scores as a predictor of length of stay in general surgery: a prospective cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43282 Thu 15 Sep 2022 12:23:29 AEST ]]> The effect of preoperative skin preparation on clinical outcomes with incisional surgery: a network meta-analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52228 Thu 05 Oct 2023 10:31:13 AEDT ]]> Barrier wound protection decreases surgical site infection in open elective colorectal surgery: a randomized clinical trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10947 Sat 24 Mar 2018 08:14:16 AEDT ]]> Antiseptic Skin Preparation Agents to Prevent Surgical Site Infection in Colorectal Surgery: A 3-Armed Randomized Controlled Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48940 Mon 17 Apr 2023 14:57:53 AEST ]]> Use of caller ID and text messaging from cell phones to increase response rates in patient surveys https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54731 Mon 11 Mar 2024 14:12:22 AEDT ]]> Randomized clinical trial to assess the ideal mode of delivery for local anaesthetic abdominal wall blocks https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41269 Mon 01 Aug 2022 09:49:35 AEST ]]> A Systematic Review and Meta-Analysis of Intra-Operative Surgical Site Sampling: Culture versus Culture-Independent Techniques in Predicting Downstream Surgical Site Infection https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53162 Fri 17 Nov 2023 12:00:09 AEDT ]]> Tranexamic Acid for Lower GI Hemorrhage: A Randomized Placebo-Controlled Clinical Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41856 18 years with lower GI hemorrhage requiring hospital admission from November 2011 to January 2014 were screened for trial eligibility (N = 265). INTERVENTIONS: A total of 100 patients were recruited after exclusions and were randomly assigned 1:1 to either tranexamic acid or placebo. MAIN OUTCOME MEASURES: The primary outcome was blood loss as determined by reduction in hemoglobin levels. The secondary outcomes were transfusion rates, transfusion volume, intervention rates for bleeding, length of hospital stay, readmission, and complication rates. RESULTS: There was no difference between groups with respect to hemoglobin drop (11 g/L of tranexamic acid vs 13 g/L of placebo; p = 0.9445). There was no difference with respect to transfusion rates (14/49 tranexamic acid vs 16/47 placebo; p = 0.661), mean transfusion volume (1.27 vs 1.93 units; p = 0.355), intervention rates (7/49 vs 13/47; p = 0.134), length of hospital stay (4.67 vs 4.74 d; p = 0.934), readmission, or complication rates. No complications occurred as a direct result of tranexamic acid use. LIMITATIONS: A larger multicenter trial may be required to determine whether there are more subtle advantages with tranexamic acid use in some of the secondary outcomes. CONCLUSIONS: Tranexamic acid does not appear to decrease blood loss or improve clinical outcomes in patients presenting with lower GI hemorrhage in the context of this trial. see Video Abstract at https://links.lww.com/DCR/A453.]]> Fri 12 Aug 2022 17:04:19 AEST ]]>